11-valent recombinant human papilloma virus vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00264732)
Timeline
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- amolimogene
- amolimogene
- zyc101a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05262010 | Phase 3 | Jun 4, 2022 | Chengdu Institute of Biological Products Co.,Ltd., Government of China, National Vaccine and Serum Institute, China |
| NCT04436133 | Phase 2 | Jun 22, 2020 | Chengdu Institute of Biological Products Co.,Ltd., Government of China, National Vaccine and Serum Institute, China |
| NCT04083196 | Phase 1 | Sep 7, 2019 | Chengdu Institute of Biological Products Co.,Ltd., Government of China, National Vaccine and Serum Institute, China |
| NCT00264732 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2005 | Eisai |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chengdu Institute of Biological Products Co.,Ltd. | Government | 3 | 0 | 3 | 2019 |
| Government of China | Government | 3 | 0 | 3 | 2019 |
| National Vaccine and Serum Institute, China | For profit | 3 | 3 | 3 | 2019 |
| Eisai | For profit | 1 | 1 | 1 | 2005 |
4 organizations
Page 1 / 1